WCLC 2025 - Posters & ePosters-P1.11.34 First-Line Camrelizumab Plus Chemotherapy in 3004 Patients With Advanced Non-Squamous NSCLC: A Nationwide Retrospective Study

P1.11.34 First-Line Camrelizumab Plus Chemotherapy in 3004 Patients With Advanced Non-Squamous NSCLC: A Nationwide Retrospective Study

Back to course

Pdf Summary

This nationwide retrospective observational study evaluated the first-line use of camrelizumab combined with chemotherapy in 3004 patients with advanced non-squamous non-small cell lung cancer (NSCLC) across China from 2019 to 2022. The real-world cohort was older (median age 65 vs. 59 years in the phase 3 CameL trial) and included more vulnerable patients, such as 7.7% with ECOG performance status 2, who were excluded from CameL. Additionally, 5% received camrelizumab with single-agent chemotherapy due to poor tolerance, whereas CameL participants all received platinum-based doublet chemotherapy.<br /><br />At a median follow-up of 25.6 months, the median overall survival (OS) was 25.9 months (95% CI: 24.8-26.8), closely aligning with the 27.1 months (95% CI: 21.9-31.5) OS reported in the updated 5-year CameL results. Safety data from 1002 patients showed a 78.8% incidence of any-grade treatment-emergent adverse events and 15.7% for grade 3 events.<br /><br />These findings demonstrate that in a broader, older, and clinically diverse population, camrelizumab plus chemotherapy maintains a comparable survival benefit to the controlled CameL study, supporting its expanded clinical use. The study is ongoing to enroll more patients and extend follow-up, with future reporting planned on 3- to 5-year real-world OS outcomes. The research was conducted by the Shandong Cancer Hospital and Jiangsu Hengrui Pharmaceuticals, who also funded the study.<br /><br />In conclusion, this large-scale real-world evidence confirms the efficacy and manageable safety profile of camrelizumab plus chemotherapy as a first-line treatment for advanced non-squamous NSCLC, justifying broader application beyond clinical trial settings. Further long-term data will provide additional insights into sustained survival benefits.

Asset Subtitle

Zhonghui Wei

Meta Tag

Speaker Zhonghui Wei

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

camrelizumab

chemotherapy

non-squamous non-small cell lung cancer

NSCLC

real-world study

overall survival

treatment-emergent adverse events

first-line treatment

China

clinical outcomes